Atomoxetine
- PDF / 151,107 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 0 Downloads / 158 Views
1 S
Exacerbation of developmental stuttering following off-label use: case report A 14-year-old boy developed exacerbation of developmental stuttering during off-label treatment with atomoxetine for stuttering and attention deficit hyperactivity disorder (ADHD). The boy, who had a history of developmental stuttering and ADHD, started receiving off-label treatment atomoxetine 25 mg/day, which was gradually increased to 40 mg/day. However, within 3 weeks of atomoxetine treatment initiation, his stuttering aggravated notably. Therefore, the boy’s dose of atomoxetine was decreased back to 25 mg/day, but the worsening of stuttering persisted. Periods of variable length, lasting from 10 days to 3 months were reported during which the intensity and frequency of stuttering increased or decreased without any triggering factor or event. Atomoxetine was suspected to be responsible for the exacerbation of stuttering. Therefore, atomoxetine was discontinued at 7th week. After 10 days of atomoxetine discontinuation, the stuttering regressed to the previous level. He then started receiving off-label treatment with methylphenidate 10 mg/day, which was gradually increased to 18 mg/day from the second week. At a follow-up after 3 weeks, the stuttering reduced dramatically and the severity of ADHD symptoms decreased. Methylphenidate 27 mg/day was continued for more than 1 year and sustained improvement of the stuttering was noted. Cicek AU. Aggravating influence of atomoxetine on the severity of stuttering and its successful treatment with methylphenidate: A case report. Dusunen Adam 33: 210-213, 803514181 No. 2, Jan 2020. Available from: URL: http://doi.org/10.14744/DAJPNS.2020.00081
0114-9954/20/1830-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 14 Nov 2020 No. 1830
Data Loading...
